Ceribell, Inc. ( (CBLL) ) has released its Q1 earnings. Here is a breakdown of the information Ceribell, Inc. presented to its investors.
Ceribell, Inc. is a medical technology company specializing in the diagnosis and management of serious neurological conditions, utilizing a unique point-of-care EEG platform powered by AI algorithms. In its first quarter of 2025, Ceribell reported a significant revenue increase of 42% compared to the previous year, totaling $20.5 million. The company also achieved an impressive gross margin of 88% and expanded its active accounts to 558. Notably, Ceribell received FDA clearance for its Clarity™ algorithm for patients aged one and older and became the first medical device company to receive FedRAMP High authorization. Key financial metrics showed a rise in product and subscription revenues, with product revenue reaching $15.6 million and subscription revenue at $4.9 million. Despite increased operating expenses due to strategic investments, the company ended the quarter with a net loss of $12.8 million. Looking ahead, Ceribell has raised its revenue guidance for 2025, anticipating growth of 27% to 33%, as it continues to focus on expanding its market presence and product offerings.